Editorial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2025; 17(6): 105085
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.105085
Prognostic value of post-neoadjuvant immunochemotherapy hypercoagulation in gastric cancer patients undergoing surgery
Meng-Jie Quan, Qiang Lin
Meng-Jie Quan, Qiang Lin, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, Renqiu 062552, Hebei Province, China
Author contributions: Quan MJ wrote the manuscript; Lin Q conceived and designed the study, and revised the manuscript. All authors have read and approved the final manuscript.
Conflict-of-interest statement: All authors declare that there is no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qiang Lin, MD, PhD, Professor, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, No. 8 Huizhan Avenue, Renqiu 062552, Hebei Province, China. billhappy001@163.com
Received: January 15, 2025
Revised: April 1, 2025
Accepted: April 10, 2025
Published online: June 15, 2025
Processing time: 150 Days and 3.7 Hours
Core Tip

Core Tip: The prognosis of patients with locally advanced gastric cancer undergoing neoadjuvant immunochemotherapy (NICT) plus radical surgery varies. Post-NICT hypercoagulation may act as a prognostic indicator. However, standardized methods for assessing cancer-associated hypercoagulation are lacking. Future research should concentrate on identifying more precise and efficient biomarkers for assessing cancer-associated hypercoagulation to refine prognostic evaluation and guide individualized treatment.